S Lotrič-Furlan1, P Bogovič1, T Avšič-Županc2, M Jelovšek2, L Lusa3, F Strle1. 1. Department of Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia. 2. Medical Faculty, Institute for Microbiology and Immunology, Ljubljana, Slovenia. 3. Faculty of Medicine, Institute for Biostatistics and Medical Informatics, University of Ljubljana, Ljubljana, Slovenia.
Abstract
BACKGROUND: Information on tick-borne encephalitis (TBE) in patients already vaccinated against the disease is limited. OBJECTIVES: To compare the course and outcome in patients with vaccination breakthrough TBE with findings in patients who developed TBE without previous vaccination. METHODS: All adult patients diagnosed with TBE at a single medical centre during a 16-year period and who had received at least two doses of TBE vaccine before the onset of illness qualified for the study. For each patient with breakthrough TBE, two unvaccinated sex- and age-matched patients, diagnosed with TBE in the same year, were included for comparison. RESULTS: Amongst 2332 patients diagnosed with TBE in the period 2000-2015, 39 (1.7%) had been vaccinated against the disease. Their median age was 59 (20-83) years; 22 of 39 (56.4%) were male. In comparison with unvaccinated patients with TBE, those with breakthrough disease more often experienced a monophasic course of illness (P = 0.006), had a higher CSF leucocyte count (P = 0.005), more often had urine retention (P = 0.012), more often needed ICU treatment (P = 0.009), were hospitalized for longer (P = 0.002) and had more severe acute illness (P = 0.004 for simple clinical assessment, P = 0.001 for severity score). CONCLUSION: In addition to several findings corroborating previous results in patients with vaccination breakthrough TBE, such as older age and the presence of a particular specific serum antibody pattern indicating anamnestic response, findings in this study indicate that the acute illness in patients with breakthrough TBE is more severe than in unvaccinated sex- and age-matched patients who develop the disease.
BACKGROUND: Information on tick-borne encephalitis (TBE) in patients already vaccinated against the disease is limited. OBJECTIVES: To compare the course and outcome in patients with vaccination breakthrough TBE with findings in patients who developed TBE without previous vaccination. METHODS: All adult patients diagnosed with TBE at a single medical centre during a 16-year period and who had received at least two doses of TBE vaccine before the onset of illness qualified for the study. For each patient with breakthrough TBE, two unvaccinated sex- and age-matched patients, diagnosed with TBE in the same year, were included for comparison. RESULTS: Amongst 2332 patients diagnosed with TBE in the period 2000-2015, 39 (1.7%) had been vaccinated against the disease. Their median age was 59 (20-83) years; 22 of 39 (56.4%) were male. In comparison with unvaccinated patients with TBE, those with breakthrough disease more often experienced a monophasic course of illness (P = 0.006), had a higher CSF leucocyte count (P = 0.005), more often had urine retention (P = 0.012), more often needed ICU treatment (P = 0.009), were hospitalized for longer (P = 0.002) and had more severe acute illness (P = 0.004 for simple clinical assessment, P = 0.001 for severity score). CONCLUSION: In addition to several findings corroborating previous results in patients with vaccination breakthrough TBE, such as older age and the presence of a particular specific serum antibody pattern indicating anamnestic response, findings in this study indicate that the acute illness in patients with breakthrough TBE is more severe than in unvaccinated sex- and age-matched patients who develop the disease.
Authors: Kim Blom; Angelica Cuapio; J Tyler Sandberg; Renata Varnaite; Jakob Michaëlsson; Niklas K Björkström; Johan K Sandberg; Jonas Klingström; Lars Lindquist; Sara Gredmark Russ; Hans-Gustaf Ljunggren Journal: Front Immunol Date: 2018-09-26 Impact factor: 7.561
Authors: Andrey L Matveev; Irina V Kozlova; Oleg V Stronin; Yana A Khlusevich; Elena K Doroshchenko; Ivan K Baykov; Oksana V Lisak; Ljudmila A Emelyanova; Olga V Suntsova; Vera A Matveeva; Julia S Savinova; Nina V Tikunova Journal: PLoS One Date: 2019-04-08 Impact factor: 3.240
Authors: Karin E Hansson; Anja Rosdahl; Mona Insulander; Sirkka Vene; Lars Lindquist; Sara Gredmark-Russ; Helena H Askling Journal: Clin Infect Dis Date: 2020-01-02 Impact factor: 9.079
Authors: J N Wagner; M Sonnberger; A Troescher; I Krehan; A Hauser; J Panholzer; T J von Oertzen Journal: Eur J Neurol Date: 2020-05-19 Impact factor: 6.089
Authors: Bo Albinsson; Anu E Jääskeläinen; Kairi Värv; Mateja Jelovšek; Corine GeurtsvanKessel; Sirkka Vene; Josef D Järhult; Chantal Reusken; Irina Golovljova; Tatjana Avšič-Županc; Olli Vapalahti; Åke Lundkvist Journal: Euro Surveill Date: 2020-03